EUVIMEDAvasta EUVIMED
StudienprotokollOpen access

Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial

Katrina M Oselinsky iD, Emily B Hill iD, Danielle M Ostendorf iD, Zhaoxing Pan iD, Kristen Bing iD, Liza T Wayland iD, Chloe Simpson iD, Kevin C Clark iD, Anaeli Sandoval iD, Elizabeth A Thomas iD, Ryan J Marker iD, Peter Kabos iD and 2 more

JMIR Research Protocols · 2026-07-23 · 15 · e86281-e86281

DOI: 10.2196/86281 ↗

At a glance

Studienprotokoll in JMIR Research Protocols, published online on 2026-07-23. Written by Katrina M Oselinsky and 13 co-authors. Institution: Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, 12348 E Montview Blvd, A…. Major MEDLINE topics: Breast Neoplasms, Obesity, Cancer Survivors, Overweight. 67 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Background

Mounting evidence underscores the adverse effects of excess body weight during cancer survivorship, yet many breast cancer survivors struggle to maintain a healthy weight (approximately 70% have overweight or obesity [OW/OB]). Daily caloric restriction with increased physical activity is the standard behavioral weight loss approach; however, many fail to achieve clinically meaningful (>5%) weight loss, emphasizing the need for innovative interventions. A recent investigation found that a behavioral weight loss program focusing on 4:3 intermittent fasting (4:3 IMF) produced 60% greater weight loss among healthy adults with OW/OB with no history of cancer than a program focused on daily caloric restriction. Given these promising results and the need for innovative weight loss strategies among breast cancer survivors, studies testing 4:3 IMF among breast cancer survivors are warranted.

Objective

This investigation aimed to evaluate the feasibility, acceptability, and safety of a 4:3 IMF behavioral weight loss program tailored to breast cancer survivors, and to examine exploratory clinical outcomes (eg, body weight, diet adherence, and physical activity) in relation to prespecified thresholds that will inform whether adjustments to the program are needed prior to progression to a larger trial.

Methods

In this proof-of-concept feasibility study, individuals with stage I-III breast cancer who have OW/OB and are post–primary therapy will enroll in a 6-month behavioral weight-loss intervention using a 4:3 IMF dietary strategy. Participants will complete a modified fast of approximately 500 kcal per day on 3 non–consecutive days per week, with ad libitum intake the other 4 days per week. Participants will receive virtual, group-based education from a registered dietitian nutritionist that includes a focus on cancer-specific nutrition guidelines. They will also receive in-person, individualized exercise support from an established exercise oncology program to target cancer-specific exercise guidelines. Intervention feasibility will be assessed via participant recruitment, retention, and education class attendance. Acceptability of Intervention Measure, Intervention Appropriateness Measure, Net Promoter Scores, and focus group interviews will be used to assess program acceptability. Proof-of-concept will be evaluated based on whether prespecified thresholds for changes in exploratory clinical outcomes are met. This information will be used to inform progression to a larger trial.

Results

This study was funded in January 2022. Data collection began in May 2024 and is ongoing as of April 2026. Recruitment was completed in September 2025 with 31 participants. Study volunteers are currently participating in the 6-month intervention, with data collection anticipated to be completed by Summer 2026, data analysis to begin in Summer/Fall 2026, and initial study results expected by early 2027.

Conclusions

This study aimed to examine feasibility, acceptability, and safety of a 4:3 IMF intervention among breast cancer survivors. Data from this study will be used to refine the 4:3 IMF intervention for delivery in a future randomized efficacy trial.

Subjects

MeSH terms (MEDLINE)

Breast NeoplasmsObesityCancer SurvivorsOverweightWeight Reduction ProgramsHumansFeasibility StudiesFemaleIntermittent FastingNeoplasm StagingWeight LossProof of Concept StudyAdultMiddle AgedPatient Acceptance of Health Care

Author keywords

behavioral weight losscancerdietintermittent fastingphysical activity

Authors and institutions

  • Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, 12348 E Montview Blvd, Aurora, CO, 80045, United States, 1 303-724-0624.
  • Anschutz Health and Wellness Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • University of Colorado Cancer Center, Aurora, CO, United States.
  • Section of Nutrition, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • Department of Kinesiology, Recreation, and Sport Studies, University of Tennessee at Knoxville, Knoxville, TN, United States.
  • Section of Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

ORCID profiles: Katrina M Oselinsky, Emily B Hill, Danielle M Ostendorf, Zhaoxing Pan, Kristen Bing, Liza T Wayland, Chloe Simpson, Kevin C Clark, Anaeli Sandoval, Elizabeth A Thomas, Ryan J Marker, Peter Kabos, Paul S MacLean, Victoria A Catenacci

Funding

  • NCI NIH HHS
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS

Cite

APA

Oselinsky, K. M., Hill, E. B., Ostendorf, D. M., Pan, Z., Bing, K., Wayland, L. T., Simpson, C., Clark, K. C., Sandoval, A., Thomas, E. A., Marker, R. J., Kabos, P., MacLean, P. S., & Catenacci, V. A. (2026). Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial. JMIR Research Protocols, 15, e86281-e86281. https://doi.org/10.2196/86281

Vancouver

Oselinsky KM, Hill EB, Ostendorf DM, Pan Z, Bing K, Wayland LT, et al. Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial. JMIR Research Protocols. 2026;15:e86281-e86281. doi:10.2196/86281

BibTeX
@article{Oselinsky2026,
  author = {Oselinsky, Katrina M and Hill, Emily B and Ostendorf, Danielle M and Pan, Zhaoxing and Bing, Kristen and Wayland, Liza T and Simpson, Chloe and Clark, Kevin C and Sandoval, Anaeli and Thomas, Elizabeth A and Marker, Ryan J and Kabos, Peter and MacLean, Paul S and Catenacci, Victoria A},
  title = {Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e86281--e86281},
  doi = {10.2196/86281}
}
Start for free →